FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
Iason Psilopatis, Christos Damaskos, Anna Garmpi, Panagiotis Sarantis, Evangelos Koustas, Efstathios Antoniou, Dimitrios Dimitroulis, Gregory Kouraklis, Michalis V. Karamouzis, Kleio Vrettou, Γεώργιος Μαρίνος, Konstantinos Kontzoglou, Nikolaos Garmpis
Abstract
Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.